H. LeBlanc

发表

Death Receptor Recruitment of Endogenous Caspase-10 and Apoptosis Initiation in the Absence of Caspase-8*

J. Blenis, A. Gazdar, A. Virmani, 2001, The Journal of Biological Chemistry.

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis.

Li-an Xu, M. Yellin, G. Nichol, 2012, Arthritis and rheumatism.

In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

A. Korman, R. T. Bunch, M. Selby, 2014, Cancer Immunology Research.

Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity

Sean C. Bendall, Michael N. Alonso, J. Melrose, 2020, Nature Cancer.

Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax

Peter Schow, D. Lawrence, A. Ashkenazi, 2002, Nature Medicine.

Apo2L/TRAIL and its death and decoy receptors

A. Ashkenazi, H. LeBlanc, Heidi N. Leblanc, 2003, Cell Death and Differentiation.

TWEAK Attenuates the Transition from Innate to Adaptive Immunity

D. Lawrence, D. Danilenko, H. Maecker, 2005, Cell.

A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer

J. Sage, Kwon-Sik Park, D. Menezes, 2018, Clinical Cancer Research.

Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Michael N. Alonso, E. Perez, D. Juric, 2021 .